Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
NCT Number: NCT01950260
The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2 / Phase 3
Rochester, Minnesota, 55905, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-all adult patients (ages 18-70 years) with Graves' Disease (GD) who will receive radioactive iodine (RAI) ablation of the thyroid gland for treatment of GD
Exclusion criteria
Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
Other names: Thyroid hormone
Placebo to start at 4 weeks after RAI
Time frame: 8 weeks
Incidence of overt hypothyroidism at 8 weeks post radioactive iodine treatment (RAI). Overt hypothyroidism was defined as thyroid stimulating hormone (TSH) test result > 3.0 milliunits per liter (mIU/L) or thyroid hormone free T4 (fT4) < 0.8 nanograms per deciliter (ng/dL). Free T4 is the portion of total T4 thyroid hormone that is available to your tissues in your bloodstream.
Time frame: 4 weeks, 8 weeks
The mean change in Quality of life scores was measured by the Hypothyroid-Health Related Quality of Life (HRQL) questionnaire. This questionnaire consists of 27 questions specifying the severity of the discomfort or symptoms of hypothyroidism using a 5 point scale for each question with "not at all"=1 to "all the time"=5. Higher scores are associated with a lower quality of life. The change between weeks 4 and 8 were assessed using a hierarchical linear model. The primary parameter of interest from the model was the treatment by time interaction term. Time was a collection of indicator values representing each assessment point.
Time frame: 4 weeks, 8 weeks
The mean change in quality of life scores was measured by the Thyroid Specific Questionnaire (TSQ). This questionnaire consists of 12 questions ranked on a four-point scale for each question where 0 is 'better than usual' and 3 is 'much less than usual'. A higher score indicates higher levels of dissatisfaction and a lower quality of life. The change between weeks 4 and 8 were assessed using a hierarchical linear model. The primary parameter of interest from the model was the treatment by time interaction term. Time was a collection of indicator values representing each assessment point.
Mayo Clinic
Other
Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01885533
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Newcastle upon Tyne, England, United Kingdom
View Trial DetailsNCT02384668
Autoimmune Diseases, Endocrine System Diseases
Aarhus C, Denmark
View Trial DetailsNCT04383795
Autoimmune Diseases, Endocrine System Diseases
Seoul, South Korea
View Trial DetailsNCT02904330
Autoimmune Diseases, Endocrine System Diseases
Liverpool, United Kingdom
View Trial Details